Molecular tumor board in advanced sarcoma: treatment implementation and clinical outcomes in a real-world cohort
- 1Albert-Einstein-Allee 23, 89081 Ulm, Germany
- 2Ulm, Germany
Abstract
Purpose Advanced sarcomas remain therapeutically challenging. We evaluated treatment implementation and clinical outcomes after molecular tumor board recommendations. Methods We retrospectively analyzed 125 sarcoma patients discussed in our multidisciplinary Molecular and Familial Tumor Board between 2017 and 2023. Clinical benefit was assessed by treatment implementation and by the ratio of progression-free survival on molecularly guided therapy versus the preceding treatment line (PFS2/PFS1). Overall survival (OS) was measured from first board discussion. Results A total of 252 pathogenic or likely pathogenic variant records across 133 genes were identified. Molecular profiling enabled therapy recommendations in 71 of 125 patients (56.8%), with treatment implementation in 41 (32.8%). PFS2/PFS1 evaluation was feasible in 29 patients, and nine (31.0%) had a documented ratio > 1.3. Median PFS2 was 102 days (95% CI 63–233). Two of seven patients (28.6%) receiving poly(ADP-ribose) polymerase (PARP) inhibitor-containing regimens had ratios > 1.3. Median OS in 124 patients was 14.6 months (95% CI 11.7–18.5; global log-rank p = 0.220). Conclusion Molecular tumor board-guided therapy identified treatment options for selected sarcoma patients. Prolonged disease control in individual PARP-treated cases provides a positive signal that warrants prospective evaluation.
Related
- Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real‐World Implementation and Clinical Outcomes
- Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.
- Molecular and Clinical Heterogeneity in Resected Biliary Tract Cancer: A Single-Center Analysis of Treatment Patterns and Oncologic Outcomes
- Shared Decision-Making and Decision Support in Advanced Chronic Kidney Disease: A Systematic Review of Models, Treatment Pathways, and Patient-Centered Outcomes
- Effectiveness of a Molecular Tumor Board in Making Personalized Treatment Recommendations for Patients with Advanced Cancer
BibTeX
@article{weinfurtner2026molecular,
title = {{Molecular tumor board in advanced sarcoma: treatment implementation and clinical outcomes in a real-world cohort}},
author = {Christoph Weinfurtner and Moritz Kaupp-Merkle and Ralf Marienfeld and Uwe Gerstenmaier and Jakob Niewöhner and Tobias Kolb and Axel Fürstberger and Sonja Dahlum and Paul Herzog and Ambros J. Beer and Regine Mayer-Steinacker and Meinrad Beer and Thomas F. E. Barth and Thomas Seufferlein and Nadine T. Gaisa and Mathias Wittau and Stephan Stilgenbauer and Alexandra von Baer and Markus Schultheiß and Reiner Siebert and Wolfgang Thaiss and Hartmut Döhner and Verena I. Gaidzik},
journal = {Journal of cancer research and clinical oncology},
year = {2026},
month = oct,
doi = {10.1007/s00432-026-06651-1},
url = {https://europepmc.org/article/PMC/PMC13691023},
note = {CC BY},
}
RIS
TY - JOUR
TI - Molecular tumor board in advanced sarcoma: treatment implementation and clinical outcomes in a real-world cohort
AU - Christoph Weinfurtner
AU - Moritz Kaupp-Merkle
AU - Ralf Marienfeld
AU - Uwe Gerstenmaier
AU - Jakob Niewöhner
AU - Tobias Kolb
AU - Axel Fürstberger
AU - Sonja Dahlum
AU - Paul Herzog
AU - Ambros J. Beer
AU - Regine Mayer-Steinacker
AU - Meinrad Beer
AU - Thomas F. E. Barth
AU - Thomas Seufferlein
AU - Nadine T. Gaisa
AU - Mathias Wittau
AU - Stephan Stilgenbauer
AU - Alexandra von Baer
AU - Markus Schultheiß
AU - Reiner Siebert
AU - Wolfgang Thaiss
AU - Hartmut Döhner
AU - Verena I. Gaidzik
PY - 2026
DA - 2026/10/01
JO - Journal of cancer research and clinical oncology
DO - 10.1007/s00432-026-06651-1
UR - https://europepmc.org/article/PMC/PMC13691023
AB - Purpose Advanced sarcomas remain therapeutically challenging. We evaluated treatment implementation and clinical outcomes after molecular tumor board recommendations. Methods We retrospectively analyzed 125 sarcoma patients discussed in our multidisciplinary Molecular and Familial Tumor Board between 2017 and 2023. Clinical benefit was assessed by treatment implementation and by the ratio of progression-free survival on molecularly guided therapy versus the preceding treatment line (PFS2/PFS1). Overall survival (OS) was measured from first board discussion. Results A total of 252 pathogenic or likely pathogenic variant records across 133 genes were identified. Molecular profiling enabled therapy recommendations in 71 of 125 patients (56.8%), with treatment implementation in 41 (32.8%). PFS2/PFS1 evaluation was feasible in 29 patients, and nine (31.0%) had a documented ratio > 1.3. Median PFS2 was 102 days (95% CI 63–233). Two of seven patients (28.6%) receiving poly(ADP-ribose) polymerase (PARP) inhibitor-containing regimens had ratios > 1.3. Median OS in 124 patients was 14.6 months (95% CI 11.7–18.5; global log-rank p = 0.220). Conclusion Molecular tumor board-guided therapy identified treatment options for selected sarcoma patients. Prolonged disease control in individual PARP-treated cases provides a positive signal that warrants prospective evaluation.
SN - 0171-5216
SN - 1432-1335
ER -